These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 17973781

  • 1. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J, Störk S, Kung M, Waller C, Fidler F, Hoyer C, Frantz S, Weidemann F, Ertl G, Angermann CE.
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM, Perna ER, Farías EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R.
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [Abstract] [Full Text] [Related]

  • 3. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
    Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators.
    Circulation; 2003 Sep 30; 108(13):1560-6. PubMed ID: 12975259
    [Abstract] [Full Text] [Related]

  • 4. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
    Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B.
    J Am Coll Cardiol; 2006 Jan 17; 47(2):338-41. PubMed ID: 16412857
    [Abstract] [Full Text] [Related]

  • 5. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 17; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 6. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
    Päivä H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimäki T, von Bergmann K, Lütjohann D, Laaksonen R.
    Clin Pharmacol Ther; 2005 Jul 17; 78(1):60-8. PubMed ID: 16003294
    [Abstract] [Full Text] [Related]

  • 7. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
    Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Okuda K, Fukunami M.
    Am Heart J; 2007 Jun 17; 153(6):1055.e1-8. PubMed ID: 17540209
    [Abstract] [Full Text] [Related]

  • 8. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
    Dogra G, Irish A, Chan D, Watts G.
    Am J Kidney Dis; 2007 Jun 17; 49(6):776-85. PubMed ID: 17533020
    [Abstract] [Full Text] [Related]

  • 9. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
    Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV.
    J Am Coll Cardiol; 2006 Jan 17; 47(2):332-7. PubMed ID: 16412856
    [Abstract] [Full Text] [Related]

  • 10. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Darapladib Investigators.
    J Am Coll Cardiol; 2008 Apr 29; 51(17):1632-41. PubMed ID: 18436114
    [Abstract] [Full Text] [Related]

  • 11. Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
    Rifaie O, Zahran A, Nammas W.
    Anadolu Kardiyol Derg; 2012 Mar 29; 12(2):90-6. PubMed ID: 22281786
    [Abstract] [Full Text] [Related]

  • 12. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
    Huptas S, Geiss HC, Otto C, Parhofer KG.
    Am J Cardiol; 2006 Jul 01; 98(1):66-9. PubMed ID: 16784923
    [Abstract] [Full Text] [Related]

  • 13. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH, Verhoeven GW, Van Der Palen J, Dikkeschei LD, Van Tits LJ, Kolsters G, Offerman JJ, Bilo HJ, Stalenhoef AF.
    J Intern Med; 2005 May 01; 257(5):438-45. PubMed ID: 15836660
    [Abstract] [Full Text] [Related]

  • 14. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
    Kappelle PJ, Zwang L, Huisman MV, Banga JD, Sluiter WJ, Dallinga-Thie GM, Dullaart RP.
    Expert Opin Ther Targets; 2009 Jul 01; 13(7):743-51. PubMed ID: 19505224
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Jul 01; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 16. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.
    Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP, Niebuhr U, Christensen JH, Toft E.
    Int J Cardiol; 2006 Aug 28; 111(3):436-41. PubMed ID: 16290290
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
    Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, Yilmaz A, Daniel WG, Garlichs CD.
    Clin Sci (Lond); 2009 Jan 28; 116(1):45-52. PubMed ID: 18459941
    [Abstract] [Full Text] [Related]

  • 19. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
    Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.
    Transplant Proc; 2005 Nov 28; 37(9):3808-12. PubMed ID: 16386546
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM, Davidson MH, Shear CL, Revkin JH.
    J Am Coll Cardiol; 2006 Nov 07; 48(9):1782-90. PubMed ID: 17084250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.